知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.033 秒)

    Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
    3.
    发明申请
    Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes 失效
    核酸/嵌段共聚物/阳离子表面活性剂复合物的冷冻干燥方法

    公开(公告)号：US20040157789A1

    公开(公告)日：2004-08-12

    申请号：US10725009

    申请日：2003-12-02

    申请人： Vical Incorporated.

    发明人： Andrew Geall

    IPC分类号： A61K048/00 ,  C12N015/85

    CPC分类号： A61K9/19

    摘要： This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.

    摘要翻译： 本发明一般涉及包含多核苷酸，嵌段共聚物和阳离子表面活性剂的制剂的冷冻干燥。 在冷冻保护剂或填充剂的存在下，可将制剂冷冻干燥，由此在干燥制剂重构时，微粒保持其最佳尺寸，避免聚集或融合。

    CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION
    7.
    发明申请
    CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION 审中-公开
    基于多核苷酸的优化基于多核苷酸的疫苗对人体细胞病毒感染

    公开(公告)号：US20140186382A1

    公开(公告)日：2014-07-03

    申请号：US14176813

    申请日：2014-02-10

    申请人： Vical Incorporated

    发明人： Gary G. HERMANSON ,  Andrew J. Geall ,  Mary Kopke Wloch

    IPC分类号： C07K14/005 ,  A61K39/245

    CPC分类号： A61K38/16 ,  A61K35/763 ,  A61K38/162 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55555 ,  A61K2039/55572 ,  C07H21/00 ,  C07K14/005 ,  C07K14/045 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2800/22

    摘要： The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

    摘要翻译： 本发明涉及基于多核苷酸的巨细胞病毒疫苗。 特别地，本发明是可操作地编码HCMV抗原的质粒，其中用于HCMV抗原的天然存在的编码区已通过密码子优化被修饰以改善人或其他哺乳动物细胞中的翻译。 可用于本发明的HCMV抗原包括但不限于pp65，糖蛋白B（gB），IE1以及这些抗原之一的片段，变体或衍生物。 在某些实施方案中，已经删除了序列，例如pp65中的Arg435-Lys438推定的激酶和gB中的膜锚定和内细胞域。 本发明还涉及在哺乳动物例如人中诱导对HCMV的免疫应答的方法，其包括如上所述递送编码密码子优化的HCMV抗原的质粒。 本发明还涉及包含编码如上所述的密码子优化的HCMV抗原的质粒的药物组合物，并且还包含佐剂，赋形剂或免疫调节剂。

    Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
    8.
    发明申请
    Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection 有权
    密码子优化的针对人巨细胞病毒感染的基于多核苷酸的疫苗

    公开(公告)号：US20040209241A1

    公开(公告)日：2004-10-21

    申请号：US10738986

    申请日：2003-12-19

    申请人： Vical Incorporated

    发明人： Gary G. Hermanson ,  Andrew J. Geall ,  Mary Kopke Wloch

    IPC分类号： C07K014/02 ,  C12Q001/70 ,  C07H021/04

    CPC分类号： A61K38/16 ,  A61K35/763 ,  A61K38/162 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55555 ,  A61K2039/55572 ,  C07H21/00 ,  C07K14/005 ,  C07K14/045 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2800/22

    摘要： The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.

    摘要翻译： 本发明涉及基于多核苷酸的巨细胞病毒疫苗。 特别地，本发明是可操作地编码HCMV抗原的质粒，其中用于HCMV抗原的天然存在的编码区已通过密码子优化被修饰以改善人或其他哺乳动物细胞中的翻译。 可用于本发明的HCMV抗原包括但不限于pp65，糖蛋白B（gB），IE1以及这些抗原之一的片段，变体或衍生物。 在某些实施方案中，已经删除了序列，例如pp65中的Arg435-Lys438推定的激酶和gB中的膜锚定和内细胞域。 本发明还涉及在哺乳动物例如人中诱导对HCMV的免疫应答的方法，其包括如上所述递送编码密码子优化的HCMV抗原的质粒。 本发明还涉及包含编码如上所述的密码子优化的HCMV抗原的质粒的药物组合物，并且还包含佐剂，赋形剂或免疫调节剂。